(November 16, 2015, 10:36 AM EST) -- WASHINGTON, D.C. — Relying heavily on the post-trial factual findings of a Delaware federal judge, the Federal Circuit U.S. Court of Appeals on Nov. 12 upheld findings that four asserted pharmaceutical patents are invalid as anticipated or obvious, while a fifth patent was not invalid and infringed (Cubist Pharmaceuticals Inc. v. Hospira Inc., Nos. 15-1197, -1204, -1259, Fed. Cir.).

(Decision available. Document #16-151130-004Z.)

According to the panel of Circuit Judges Evan J. Wallach, William C. Bryson and Todd M. Hughes, there is nothing clearly erroneous in...